Mitsui Chemicals, Inc. has signed an agreement to acquire JSR Corp., a Tokyo-based developer and manufacturer of semiconductor materials including photoresists, from investment funds managed by JIC Capital, Ltd. The transaction is valued at ¥1.84 trillion ($11.6 billion) including debt and would make JSR a consolidated subsidiary of Mitsui Chemicals.
Under the agreement, Mitsui Chemicals will buy all JSR common shares held by JIC PEFJ1 Limited Partnership and JIC PEF1 Limited Partnership, jointly with Development Bank of Japan Inc. (DBJ), which will invest ¥200 billion ($1.3 billion). The price comprises an equity value of ¥1.3921 trillion ($8.8 billion) plus ¥447.9 billion ($2.8 billion) in interest-bearing debt and other items, with the final consideration to be adjusted at closing. Mitsui Chemicals also expects to acquire JSR's Class A and Class B preferred shares, held by Mizuho Bank and DBJ, for cash; those shares are slated to convert to common shares after closing, while DBJ's common shares will convert to non-voting preferred shares.
Why JSR fits the specialty portfolio
The deal is positioned under Mitsui Chemicals' "VISION 2030" plan, which pairs a specialty chemicals pillar — Life & Healthcare Solutions, Mobility Solutions and ICT Solutions — with a Basic & Green Materials pillar centered on petrochemicals. Mitsui said JSR's advanced photoresists, customer base in semiconductor and optical fields and global reach make it a core part of its ICT Solutions domain.
The company plans to combine its MITSUI PELLICLE products and JSR's advanced photoresists in front-end processes, and its ICROS Tape with thick-film resists in back-end processes. It targets annual incremental profit of about ¥40 billion ($253 million) by fiscal 2035 from growth and cost synergies.
Portfolio reshuffle and financing
Mitsui Chemicals first said in May 2025 that it would consider splitting off its Basic & Green Materials business; it will now add Mobility Solutions to the scope, aiming to form a polymer science company with an integrated polymer chain spanning upstream petrochemicals and downstream functional polymers. It also plans to become more asset-light in underperforming businesses, improve its cash conversion cycle and sell shareholdings. Combined with JSR's review of its life sciences business — contract research and contract development and manufacturing, which JSR treats as non-core — Mitsui expects benefits representing business value of ¥350 billion ($2.2 billion) or more.
Funding relies on a ¥1.64-trillion ($10.4-billion) bridge loan from Mitsui's principal financial institutions plus DBJ's ¥200-billion investment. Net debt/EBITDA is expected to temporarily exceed 4x after closing. To protect an "A"-category credit rating, the company plans to refinance the bridge loan within one year of closing through bank loans, bonds and equity; it aims to have the equivalent of ¥300 billion ($1.9 billion) recognized as equity by rating agencies, capping common share issuance including treasury shares at ¥150 billion ($948 million) and adding ¥300 billion of mezzanine financing, half of which is assumed to count as equity.
A shelf registration for up to ¥150 billion of common shares becomes effective Nov. 17, 2026, and runs through Nov. 16, 2028, with proceeds going toward partial repayment of the bridge loan. SMBC Nikko Securities and Mizuho Securities are expected to be the primary underwriters.
Assets, financials and approvals
Four JSR affiliates will become specified subsidiaries of Mitsui Chemicals: Inpria Corp. (Corvallis, Ore.), KBI Biopharma, Inc. (Durham, N.C.), JSR North America Holdings, Inc. (Sunnyvale, Calif.) and JSR Life Sciences, LLC (Sunnyvale, Calif.). JSR reported revenue of ¥440.7 billion ($2.8 billion), consolidated operating profit of ¥40.5 billion ($256 million) and profit attributable to owners of ¥59.3 billion ($375 million) for the fiscal year ended March 2026.
The transaction is subject to competition-law and foreign-investment approvals in Japan and overseas. Mitsui Chemicals is aiming to close in the second half of the fiscal year ending March 2028 and expects the impact on results for the fiscal year ending March 2027 to be minor. Currency conversions cited in the announcement were based on ¥158.2 per $1.
